BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3322544)

  • 1. The potential of oncogene products as tumour markers.
    Chan S; Sikora K
    Cancer Surv; 1987; 6(2):185-207. PubMed ID: 3322544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenes and oncoproteins as tumor markers.
    Pillai R
    Eur J Surg Oncol; 1992 Oct; 18(5):417-24. PubMed ID: 1426290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of c-myc protein in human breast tumours determined by a sensitive ELISA technique.
    Spandidos DA; Field JK; Agnantis NJ; Evan GI; Moore JP
    Anticancer Res; 1989; 9(4):821-6. PubMed ID: 2683996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of c-myc in non-malignant and pre-malignant gastrointestinal disorders.
    Ciclitira PJ; Macartney JC; Evan G
    J Pathol; 1987 Apr; 151(4):293-6. PubMed ID: 3295155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of c-myc, c-myb, c-fos, c-sis and c-fms proto-oncogene expression and of CSF-1 transcripts and protein by phorbol diester in human malignant histiocytosis DEL cell line with 5q 35 break point.
    Gogusev J; Barbey S; Nezelof C
    Anticancer Res; 1993; 13(4):1043-7. PubMed ID: 8352523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human N-myc is closely related in organization and nucleotide sequence to c-myc.
    Kohl NE; Legouy E; DePinho RA; Nisen PD; Smith RK; Gee CE; Alt FW
    Nature; 1986 Jan 2-8; 319(6048):73-7. PubMed ID: 3510398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
    Volm M; Mattern J
    Anticancer Res; 1993; 13(6A):2021-5. PubMed ID: 8297109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncoprotein immunoreactivity in human endocrine tumours.
    Roncalli M; Springall DR; Varndell IM; Gaitonde VV; Hamid Q; Ibrahim NB; Grimelius L; Wilander E; Polak JM; Coggi G
    J Pathol; 1991 Feb; 163(2):117-27. PubMed ID: 1673155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytologic molecular detection of oncogene expression: possibilities and prospects in hemato-oncology].
    Greil R; Fasching B; Huber H
    Acta Med Austriaca; 1990; 17(1):6-10. PubMed ID: 2191534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the c-myc oncoprotein in human metaplastic epithelial cells of fibrocystic disease.
    Papamichalis G; Francia K; Karachaliou FE; Anastasiades OT; Spandidos DA
    Anticancer Res; 1988; 8(6):1217-22. PubMed ID: 3064712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oncogenes and oncogene products--possibilities and significance of their detection].
    Höfler H
    Verh Dtsch Ges Pathol; 1990; 74():319-27. PubMed ID: 1708608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
    Li BD; Bauer KD; Carney WP; Duda RB
    J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic characterization of tumor markers in human ovarian cancer cell lines.
    Kutteh WH; Miller DS; Mathis JM
    J Soc Gynecol Investig; 1996; 3(4):216-22. PubMed ID: 8796833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
    Velasco JA; Avila MA; Notario V
    Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to C-MYC and C-Ha-ras cellular oncogenes.
    Pechoux C; Chardonnet Y; Chignol MC; Noël P
    Histol Histopathol; 1994 Jan; 9(1):35-44. PubMed ID: 8003818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
    Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
    Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue.
    Spandidos DA; Pintzas A; Kakkanas A; Yiagnisis M; Mahera H; Patra E; Agnantis NJ
    Anticancer Res; 1987; 7(6):1299-304. PubMed ID: 3327455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types.
    Prins J; De Vries EG; Mulder NH
    Anticancer Res; 1993; 13(5A):1373-85. PubMed ID: 8239508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.